No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KBR240719C67500
- 0.50
- +0.40+400.00%
15min DelayClose Jul 16 16:00 ET
0.55High0.23Low
0.23Open0.10Pre Close14 Volume90 Open Interest67.50Strike Price663.00Turnover23.73%IV0.59%PremiumJul 19, 2024Expiry Date0.10Intrinsic Value100Multiplier2DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.5402Delta0.2829Gamma108.16Leverage Ratio-0.1159Theta0.0027Rho58.43Eff Leverage0.0235Vega
Intraday
- 5D
- Daily
News
Unusual Options Activity: JEF, AU and Others Attract Market Bets, JEF V/OI Ratio Reaches 307.9
EST Jul 16th Closing Delivery - In the last three hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
KBR Deal to Buy LinQuest Expected to Provide 'Compelling' Revenue Synergies, Truist Says
KBR's (KBR) $737 million deal to acquire engineering, data analytics and digital integration firm LinQuest is likely to provide "compelling" revenue synergies to the company, Truist Securities said
KBR to Acquire LinQuest for $737 Million in Cash
KBR (KBR) said Tuesday that it has agreed to acquire LinQuest, an engineering, data analytics and digital integration company, for $737 million in an all-cash transaction.The deal is expected to be
KBR to Buy LinQuest From Madison Dearborn in $737 Million Deal
By Colin Kellaher KBR has agreed to buy engineering, data-analytics and digital-integration company LinQuest from private-equity firm Madison Dearborn Partners in a $737 million cash deal. KBR on
KBR to Buy Data Analytics Firm LinQuest in $737M Deal
KBR (NYSE:KBR) said Tuesday it agreed to acquire national security space systems and technology provider LinQuest from Madison Dearborn Partners for $737M.
Express News | KBR Agrees To Acquire LinQuest, To Expand Technical Capabilities Across Air, Space And Digital Domains
Comments
KBR's revenue growth could be seen as a positive sign, despite potential sacrifice of current earnings per share. Future earnings are crucial for shareholders. Despite slower share price gains, the business may continue to perform well.
Those Who Invested in KBR (NYSE:KBR) Five Years Ago Are up 238%Given the upward trend and increased efficiency in KBR's return on capital employed, it appears to show promise. Considering the outstanding shareholder returns over the last five years, it's advisable for investors to explore if these trends will continue.
Sizable insider selling at KBR creating investor caution. Lack of insider buying combined with substantial selling seen as red flag. 1.0% insider ownership doesn't fully dispel concerns.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
+9
11
Gainers:
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
12
Read more